Filing Details
- Accession Number:
- 0001209191-17-044143
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-07-06 17:16:28
- Reporting Period:
- 2017-07-03
- Filing Date:
- 2017-07-06
- Accepted Time:
- 2017-07-06 17:16:28
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1442836 | Mersana Therapeutics Inc. | MRSN | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1219855 | James M Barrett | 1954 Greenspring Drive Suite 600 Timonium MD 21093 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2017-07-03 | 7,140,138 | $0.00 | 7,140,138 | No | 4 | C | Indirect | See Note 3 |
Common Stock | Acquisiton | 2017-07-03 | 1,000,000 | $15.00 | 8,140,138 | No | 4 | P | Indirect | See Note 3 |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Indirect | See Note 3 |
No | 4 | P | Indirect | See Note 3 |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Series A-1 Preferred Stock | Disposition | 2017-07-03 | 11,931,173 | $0.00 | 2,647,241 | $0.00 |
Common Stock | Series B-1 Preferred Stock | Disposition | 2017-07-03 | 18,001,419 | $0.00 | 4,000,314 | $0.00 |
Common Stock | Series C-1 Preferred Stock | Disposition | 2017-07-03 | 2,216,626 | $0.00 | 492,583 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect |
Footnotes
- The total represents shares received upon conversion of Series A-1, Series B-1 and Series C-1 Convertible Preferred Stock.
- Upon closing of the Issuer's initial public offering, each share of Series A-1, Series B-1 and Series C-1 Convertible Preferred Stock automatically converted into .22222 shares of Common Stock without payment of further consideration. There was no expiration date for the Series A-1, Series B-1 or Series C-1 Convertible Preferred Stock.
- The Reporting Person is a director of NEA 14 GP, LTD, which is the sole general partner of NEA Partners 14, L.P. ("NEA Partners 14"). NEA Partners 14 is the sole general partner of New Enterprise Associates 14, L.P. ("NEA 14"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 shares in which the Reporting Person has no pecuniary interest.